Daily Stock List
Guided Therapeutics, Inc. (GTHP)
PennyTrader Publisher, Pennystocktweeters.com, NYC Marketing Inc, AllPennyStocks, and Momentum Trades reported previously on Guided Therapeutics, Inc. (GTHP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
OTC Bulletin Board-listed Guided Therapeutics, Inc. is the creator of a rapid and painless testing platform. This platform is for the early detection of disease based on the Company's patented biophotonic technology that uses light to detect disease at the cellular level. The Company's first product is the LuViva® Advanced Cervical Scan - a non-invasive device used to detect cervical disease instantly and at the point of care.
LuViva® is a technologically advanced diagnostic device. It scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of pre-cancer, which may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Biophotonics is the science of generating and harnessing light to image, detect, and manipulate biological materials.
In a multi-center clinical trial, with women at risk for cervical disease, the LuViva® Advanced Cervical Scan technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. The device is used in combination with the LuViva® Cervical Guide single-use patient interface and calibration disposable.
The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use. The LuViva® Advanced Cervical Scan is now compliant with both Edition 2 and Edition 3 CE standards. It has marketing approval from Health Canada and the Singapore Health Sciences Authority, and it is under U.S. Food and Drug Administration (FDA) Premarket review.
The design of LuViva® is as a fast, painless test that, unlike Pap smears and HPV testing, does not require a tissue sample or the delay of laboratory analysis. LuViva® utilizes proprietary technology to identify cancers and precancers quickly through analyzing light reflected from the cervix. The Company is also developing a non-invasive test for the early detection of esophageal cancer using the technology platform.
In May, Guided Therapeutics announced that because of its “productive” discussion with officials of the U.S. Food and Drug Administration (FDA), it plans to submit an amendment to its premarket approval (PMA) application for the LuViva® Advanced Cervical Scan. The filing will include responses to questions raised in the agency’s September 6, 2013 not-approvable letter.
This month, Guided Therapeutics announced that the LuViva® Advanced Cervical Scan was chosen as best designed new medical device of 2014 at the 17th Annual Medical Device Excellence Awards (MDEA) ceremony held Wednesday, June 11, 2014, in combination with the MD&M East event at the Jacob K. Javits Convention Center in New York. LuViva® was chosen as the Gold Medal Winner in the Hospital Devices and Therapeutic Products’ category by a panel of independent experts because of excellence in product innovation, design and engineering achievement, end-user benefit, and cost-effectiveness in manufacturing and healthcare delivery.
Guided Therapeutics, Inc. (GTHP), closed Monday's trading session at $0.395, even for the day, on 6,500 volume with 6 trades. The average volume for the last 60 days is 43,172 and the stock's 52-week low/high is $0.1601/$0.775.
CytoSorbents Corp. (CTSO)
Wall Street Resources reported yesterday on CytoSorbents Corp. (CTSO), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.
CytoSorbents Corp. is a critical care focused corporation using blood purification to treat life-threatening illnesses in the intensive care unit. It is using this blood purification to modulate the immune system and fight multiple organ failure. The foundation of its purification technology is on biocompatible, highly porous polymer beads, which can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents’ shares trade on the OTC Bulletin Board.
The Company’s flagship product is CytoSorb®. The CytoSorb® product has approval in the European Union (EU) as a safe and effective extracorporeal cytokine filter. CytoSorb® is available for sale and clinical use in the European Union. CytoSorbents currently has a Food and Drug Administration (FDA)-approved IDE application to run a small sepsis trial in the U.S. The Company will look to conduct a pivotal sepsis study in the future as a critical step towards U.S. FDA approval.
CytoSorb® is a first-in-class extracorporeal cytokine filter. It is compatible with standard hemodialysis machines and blood pumps found in most hospitals. CytoSorb® is broadly indicated for use in any clinical situation where cytokines are elevated. The design of it is to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses.
CytoSorbents has a number of products under development. These are all based upon the same underlying blood purification technology - protected by 32 issued U.S. patents and multiple applications pending. These products include HemoDefend™, ContrastSorb, DrugSorb, and others. HemoDefend™ is under advanced development and is not yet approved in the U.S. or elsewhere. The design of the HemoDefend™ technology is to remove non-infectious contaminants in blood transfusion products.
The CytoSorb® Dosing study is a multi-center trial taking place among eight leading clinical sites in Germany. It is an extension of CytoSorbents' previous randomized controlled European Sepsis Trial (EST). There are two CytoSorb® treatment protocols undergoing evaluation in the Dosing study. One is 24 hours per day for 7 days and the other is 6 hours per day for up to 14 days, each day using a new device. Currently, only the 24-hour treatment arm is enrolling patients.
In May, CytoSorbents reported Q1 operational and financial results for the three months ended March 31, 2014. Selected Q1 2014 financial highlights include record total revenue of approximately $1.1M. The Company attained record quarterly CytoSorb® sales of $569K. This represents a sequential 81 percent increase from the previous quarter product sales of $314K, and a 223 percent increase over product sales of $176K in Q1 2013. In addition, product gross margins were greater than 60 percent. Grant income increased 152 percent to $491K versus $195K in Q1 2013.
CytoSorbents Corp. (CTSO), closed Monday's trading session at $0.92, up 24.32%, on 150,043 volume with 109 trades. The average volume for the last 60 days is 2,368 and the stock's 52-week low/high is $0.55/$0.85.
Santa Fe Gold Corp. (SFEG)
SmarTrend Newsletters reported recently on Santa Fe Gold Corp. (SFEG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Incorporated in August 1991 in the state of Delaware, Santa Fe Gold Corp. is a U.S. mining company that lists on the OTC Markets’ OTCQB. It has a general business strategy to acquire and develop mining properties amenable to low cost production. The Company has four advanced properties. These are all within the politically stable and mining friendly jurisdictions of the southwest United States. Santa Fe Gold’s intention is to build a portfolio of high-quality, diversified mineral assets with an emphasis on precious metals. The Company is based in Albuquerque, New Mexico.
Santa Fe Gold’s projects include Summit Gold-Silver, Mogollon Gold-Silver, Ortiz Gold, Black Canyon Mica, and Planet Micaceous Iron Oxide. In April 2012, the Summit silver-gold project attained commercial production. In November 2013 operations were temporarily suspended pending attainment of new financing to properly capitalize mine expansion. In addition, Santa Fe Gold’s intention is to advance the Mogollon and Ortiz gold projects.
Summit mine revenues are projected to grow to $35 million annually over the next two years ($1250 gold). Santa Fe controls the Summit mine and Lordsburg mill in southwestern New Mexico, and a substantial land position near the Lordsburg mill, consisting of the core of the Lordsburg Mining District.
In addition, the anticipation is that the Mogollon project will contribute an additional $35 million annually to revenue as early as 2015. The Ortiz project needs to go through the permitting process. However, it could commence production as early as 2017.
Last week, Santa Fe Gold announced it reached agreement with Columbus Exploration Corp. to extend the term of the Mogollon option until November 21, 2014. By making a final option payment of $950,000, Santa Fe may earn 100 percent interest in the Mogollon Project, Catron County, New Mexico. The Mogollon Project covers the majority of the Mogollon district in southwest New Mexico. This district has considerable recorded historical production of silver and gold. The project fits the Company’s strategic goal of developing new ore sources for processing by way of its Lordsburg flotation mill.
Santa Fe Gold Corp. (SFEG), closed Monday's trading session at $0.16, down 11.11%, on 84,800 volume with 17 trades. The average volume for the last 60 days is 71,903 and the stock's 52-week low/high is $0.1201/$4.00.
SANUWAVE Health, Inc. (SNWV)
PennyStocks24, RedChip, and SmallCapVoice reported recently on SANUWAVE Health, Inc. (SNWV), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTC Bulletin Board, SANUWAVE Health, Inc. is a shock wave technology company with approximately 170 devices in use globally. The Company focuses on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. Its portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses. This produces new vascularization and microcirculatory improvement. This aids in restoring the body's normal healing processes and leads to regeneration of tissue. SANUWAVE Health is headquartered in Alpharetta, Georgia.
SANUWAVE researches, designs, manufactures, markets and services its products worldwide. There are license/partnership opportunities for SANUWAVE's shock wave technology for non-medical uses, including energy, water, food and industrial markets. The Company’s plan is to apply its Pulsed Acoustic Cellular Expression (PACE®) technology in wound healing, orthopedic/spine, plastic/cosmetic, and cardiac conditions.
The Company's lead product candidate for the global wound care market, dermaPACE®, is CE marked across Europe. It has Canada, Australia, and New Zealand device license approval for the treatment of the skin and subcutaneous soft tissue. In the U.S., dermaPACE is now under the Food and Drug Administration's (FDA's) Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers.
The Company believes that it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) by way of its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment via the use of its OssaTron®, Evotron® and orthoPACE® devices in Europe, Asia, and Asia/Pacific.
SANUWAVE Health received a patent on May 20, 2014, issued by the U.S. Patent and Trademark Office (USPTO) entitled "Use of Pressure Waves for Stimulation, Proliferation, Differentiation and Post-Implantation Viability of Stem Cells." The claims of the patent (patent number 8,728,809) concern the use of shock waves for stimulation of proliferation inside the body of donor stem cells.
Mr. Kevin Richardson, Chairman of the Board of Directors of SANUWAVE Health, said, "This patent opens a totally new field for using our shock wave technology in the most advanced medical treatments that employ stem cells for tissue reconstruction."
SANUWAVE Health, Inc. (SNWV), closed Monday's trading session at $1.13, down 1.74%, on 93,056 volume with 108 trades. The average volume for the last 60 days is 275,335 and the stock's 52-week low/high is $0.94/$6.20.
Agritek Holdings, Inc. (AGTK)
Today we are reporting on Agritek Holdings, Inc. (AGTK), here at the QualityStocks Daily Newsletter.
OTCQB-listed Agritek Holdings, Inc. provides innovative, turnkey solutions for medicinal and canna-businesses located within regulated jurisdictions across the U.S. Agritek is the first fully reporting Company and pioneer within the medicinal marijuana space. The Company does not directly grow, harvest, or distribute or sell cannabis or any substances that violate United States law or the Controlled Substances Act, nor does it have any intention of so doing in the future. Agritek Holdings has offices in West Palm Beach, Florida and Denver, Colorado.
Agritek was the first public entity to offer electronically processing transactions within the medicinal marijuana sector. Agritek has a network of dispensaries and clients.
Currently, Agritek Holdings distributes vertical business products and services to regulated cannabis businesses. This includes consulting and management services related to the purchase and lease of building and land operations within regulated jurisdictions, The Mont Blunt Brand of Vaporizers and e-Cig line, and Hemp based beverages. In addition, Agritek offers equipment leasing and credit facilities for large scale grow and retail operations by way of its established banking network.
Last week, Agritek Holdings announced that Governor Rick Scott signed a bill on Monday June 16, 2014, which legalizes the use of a non-euphoric strain of marijuana to treat conditions such as epilepsy, Lou Gehrig's disease and cancer. The Senate Bill 1030 which approves the medication, and SB 1700, which protects the identities of the patients who use it, will now begin the process and clear the way for the first qualifying patients to enter the program once established by the state.
B. Michael Friedman, Chief Executive Officer of Agritek Holdings, stated, "We at Agritek Holdings have already taken preliminary steps in the hope of becoming an active participant and partner to the great state of Florida as the newly passed medical cannabis legislation begins to go into effect. Our Agricultural nursery and land previously showcased on a CBS news special report highlighting the medical marijuana industry in Florida is an ideal location with unlimited non-federal water sources, infrastructure and electricity that could act as an intermediate testing ground for licensed candidates.”
Agritek Holdings, Inc. (AGTK), closed Monday's trading session at $0.415, down 2.35%, on 29,930 volume with 6 trades. The average volume for the last 60 days is 66,046 and the stock's 52-week low/high is $0.29/$0.695.
Banjo & Matilda (BANJ)
The QualityStocks Daily Newsletter would like to spotlight Banjo & Matilda (BANJ). Today, Banjo & Matilda closed trading at $0.09, up 5.88%, on 1,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 80,727, and its 52-week low/high is $0.001/$0.018.
Banjo & Matilda (BANJ) is an emerging Australian lifestyle brand known globally for its fun sweaters and luxe cashmere basics. Big on quality and small on pretense, the company’s cashmere sweaters are spun with natural and ethically sourced yarns from goats in the highest mountains of Inner Mongolia, putting a little bespoke love into each garment with their signature XX logo hand-stitched into each right-hand corner.
Founders Belynda and Ben Macpherson wanted to create sweaters that were not only discreetly luxurious, but also captured the freedom of their lifestyle by the beach—the freshness of the ocean, warmth of the sand and soulfulness of the surf—in a range of knitwear made with supreme quality and integrity. The result being sweaters spun from the most premium of natural yarns such as fine cashmere, silk and organic cotton but supporting the opposite of “fast-fashion” in sustainability, longevity, endurance and lovability.
The brand, which has a rapidly growing loyal following, is quickly being stocked in important major and specialty retailers around the world, including Net-a-Porter, Shopbop, Harvey Nichols London, Neiman Marcus, Intermix New York, David Jones Australia and major department stores in Germany and the Middle East. Apparel is also shipped in other locations of the world through Banjo Matilda’s online store to loyal customers from Bondi to New Delhi.
Banjo & Matilda’s long-term vision is to grow distribution similarly to peers in the industry such as Vince Holding Corp. (NYSE: VNCE), which is now in more than 2,100 retail outlets, and Zadig & Voltair, which shares a similar growth pattern to the company. In just one quarter this year, Banjo & Matilda increased the number of retail outlets “doors” stocking its products by 122%. By September, the company is expected to increase the number of outlets by 433% from Q4 2013 based upon forward wholesale orders received. Disclaimer
Banjo & Matilda Company Blog
Banjo & Matilda News:
Banjo & Matilda Appoints Leading U.S. Fashion Sales Agency To Grow Distribution
Banjo & Matilda Grows Retailer Outlet Distribution in First Quarter by 122%
Banjo & Matilda Welcome Letter
Ecrypt Technologies, Inc. (ECRY)
The QualityStocks Daily Newsletter would like to spotlight Ecrypt Technologies, Inc. (ECRY). Today, Ecrypt Technologies, Inc. closed trading at $0.145, up 3.57%, on 20,480 volume with 10 trades. The stock’s average daily volume over the past 60 days is 6,269 and its 52-week low/high is $0.055/$0.28.
Ecrypt Technologies, Inc. announced today that Nüwa Executive Academy for Security, Defense and Intelligence Professionals, Stockholm, Sweden and Ecrypt formalized their strategic marketing alliance through a formal, worldwide exclusive arrangement whereby Ecrypt will promote, sell and distribute all of Nüwa Executive Academy for Security, Defense and Intelligence Professionals global academies.
Ecrypt Technologies, Inc. (ECRY) is an emerging provider of military-strength data security solutions for enterprise, government, and military. The company empowers organizations with the freedom to communicate and collaborate without risk of liability, reputation damage, competitive threat, and other negative outcomes. Ecrypt is the trusted first choice for those looking to keep their communications confidential.
Today’s businesses struggle to guard against the increasing number of dangers as a result of complicated networks built with many different components that are often individually patched to address new threats, while neglecting to close security gaps in traditional solutions. On average, data breaches and subsequent fines and litigation cost a US business $534 million every year, the highest in the world according to the Ponemon Institute.
The flagship Ecrypt solution is an integrated email and encryption server that can be quickly deployed to fortify the security of corporate communication, including attachments and mobile devices, against data breaches while eliminating phishing threats, malware infections, and spam. By using Ecrypt’s paradigm-shifting technology, companies alleviate the need for separate encryption servers with their associated bloated administration and multiple points of weakness.
Ecrypt is well positioned to benefit from increasingly demanding data confidentiality regulations such as the Health Insurance Portability and Accountability Act (HIPAA), the Federal Information Security Management Act (FISMA), and Gramm-Leach-Bliley Act (GLBA). As a result of extensive market research and working directly with organizations in multi-billion dollar industries, the company fully understands the business community’s need to maintain confidentiality, prevent data breaches, comply with government regulations, and mitigate litigation risks. Disclaimer
Ecrypt Technologies, Inc. Blog
Ecrypt Technologies, Inc. News:
Ecrypt Technologies and Nuwa™ Executive Academy for Security, Defense and Intelligence Professionals enter into a Marketing Alliance
Ecrypt Technologies and QCR form Strong Strategic Marketing Alliance
Ecrypt Technologies and Cyber Risk Pro Services Form Cyber Protection Partnership
NutraNomics, Inc. (NNRX)
The QualityStocks Daily Newsletter would like to spotlight NutraNomics, Inc. (NNRX). Today, NutraNomics, Inc. closed trading at $0.068, even for the day, on 40,260 volume with 7 trades. The stock’s average daily volume over the past 60 days is 172,234, and its 52-week low/high is $0.06/$1.48.
NutraNomics, Inc. (NNRX) is focused on the research and development of nutritional dietary supplements, skin and body care products and transdermal patches. In addition to creating formulas for hundreds of companies, the company has produced and branded its own product lines which are sold through retail and wholesale channels. Additionally the company private labels and does custom manufacturing for several supplement companies in national and international markets.
Nearly all vitamins currently on the market are isolated and/or synthetic. The human body doesn’t recognize these types of vitamins and as a result cannot absorb them because they are either missing critical nutritional components or are not food based. NutraNomics has rapidly grown its business over the past 18 years by offering superior food and plant-based products blended from the highest quality sources available for maximum bioavailability.
Today NutraNomics has sales teams in seven different countries promoting its diversified line of wholefood-based supplements, specialty formulas, and remedies. All facilities used to produce the gluten-free, non-GMO nutritional products are cGMP Compliant and FDA approved. To ensure the highest purity potency and quality, the company takes it another step forward by performing additional content testing on all raw materials used to manufacture its products.
NutraNomics is more than just a health supplement provider. As a company dedicated to supporting the worldwide community of people who want to live healthy, NutraNomics is making an impact on those who are suffering from various types of diseases that need specialized diet to enhance their lifestyle. To fulfill this mission NutraNomics has invested in clinical studies for controlling diabetes, heart disease and cancer with dietary supplements. Strong growth is anticipated to continue as the company continues to introduce cutting-edge products and taps into new markets. Disclaimer
NutraNomics, Inc. Company Blog
NutraNomics, Inc. News:
Nutranomics Whole Food Based Vitamins and Supplements Available on Amazon.com
Nutranomics Whole Food Based Vitamins and Supplements Joins Forces With Stonegate
RevNutrition.com to Carry Nutranomics Line of Non-Synthetic Supplements, Vitamins
Pan Global Corp. (PGLO)
The QualityStocks Daily Newsletter would like to spotlight Pan Global Corp. (PGLO). Today, Pan Global Corp. closed trading at $0.075, up 7.14%, on 1,039,299 volume with 39 trades. The stock’s average daily volume over the past 60 days is 364,769, and its 52-week low/high is $0.05/$0.96.
Pan Global Corp. (PGLO) is focused on building the world’s green economy by developing, building, owning, and operating the necessary infrastructure. Current opportunities are currently concentrated on developing projects in India, specifically in the areas of hydro-power generation, solar PV, geo-thermal, sustainable agriculture, and green construction.
The India growth story is frequently compared to China, which has sustained above-average annual growth for three decades, whereas India’s take-off growth began at a later stage. During the last decade, India’s growth has averaged approximately 8% per year. India is poised for high GDP growth that will be sustained for decades to come.
Within the Indian market there are available various government-backed incentives programs, including those which provide direct tariff subsidies as well as market-based tariff support through renewable energy credits. Assessing project viability on a case by case basis, Pan Global seeks to invest in projects both as owner-developers and/or as partners with other developers.
Pan Global’s business strategy is an extension of the company’s commitment to improve human well-being and social equity, while significantly reducing environmental risks and ecological scarcities. By developing a series of highly environmentally sustainable and high ROI projects, Pan Global aims to accelerate business growth. Disclaimer
Pan Global Corp. Company Blog
Pan Global Corp. News:
Pan Global, Corp. Commences Design Phase for Planned Hydroponic Greenhouse in Northern India
Pan Global, Corp. Shareholder Update: Anticipated Two Stage Completion of Small-Hydro Plant and Connection to Power Grid
Pan Global, Corp. Comments on Industry Report That the Global Green Energy Market Is Expected to Reach USD $831.99 Billion in 2019
Great Plains Holding, Inc. (GTPH)
The QualityStocks Daily Newsletter would like to spotlight Great Plains Holding, Inc. (GTPH). Today, Great Plains Holding, Inc. closed trading at $1.28, even for the day. The stock’s average daily volume over the past 60 days is 105, and its 52-week low/high is $0.75/$2.00.
Great Plains Holding, Inc. (GTPH) operates through two wholly owned subsidiaries: Ashland Holdings, LLC, focused on the real estate sector; and LiL Marc, Inc., maker of the "LiL Marc" training urinal for toddler boys. This diversification model enables Great Plains to achieve multiple revenue streams and consistently increase hard assets.
Ashland Holdings, LLC is engaged in the acquisition and operation of commercial real estate, including, but not limited to, self-storage facilities, apartment buildings, manufactured housing communities for senior citizens, and other income-producing properties. The subsidiary’s current portfolio includes a 1,400-square-foot corporate office building; an 800-square-foot warehouse for LiL Marc operations; and two adjacent parcels of land, one of which includes a manufactured home that is rented out for additional income. Ashland and LiL Marc plan to occupy one or more of the five office spaces located in the corporate office building to accommodate expected expansion. The remaining vacant offices may be leased to tenants to create a source of revenue.
LiL Marc, Inc. is Great Plains’ principal business activity. Founded in 1999, the subsidiary engages in the manufacturing and marketing of training urinals for boys in the United States. The LiL Marc boys potty training urinal looks like the full sized urinals found in public restrooms, but are manufactured on a smaller scale in proportion to the smaller size of toddlers in training. In conjunction with the roll-out of an aggressive marketing campaign for the LiL Marc product, Great Plains’ management team is building a client list of retailers with brick and mortar stores and other consumer outlets to participate in the broader retail market. With advertising strategies in place, management envisions growth and widespread distribution of the LiL Marc training urinal.
Great Plains also intends to purchase privately-owned profitable businesses owned by baby boomers looking to retire. As the company continues to execute its expansion strategy and add additional subsidiaries, all potential purchases will be reviewed by management to ensure they meet very stringent requirements. Disclaimer
Great Plains Holding, Inc. Company Blog
Great Plains Holding, Inc. News:
Great Plains Holdings, Inc. President, COO Featured in Exclusive QualityStocks Interview
Great Plains Holdings, Inc. Completes Final Phase of Real Estate Asset Project Ahead of Schedule
Great Plains Holdings, Inc. Partners With TexStar Energy for Texas Lease With Nearly 3M Barrels of Estimated Oil Reserves
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Armco Metals Holdings, Inc. (AMCO) Receives Government Approval to Import 20,000 Metric Tons of Restricted Materials Annually
- Banjo & Matilda (BANJ) Appoints Leading U.S. Fashion Sales Agency To Grow Distribution
- Big Tree Group, Inc. (BIGG) Reports Financial Results for the Full Year of 2013 Ended December 31, 2013
- Cal-Bay International, Inc. (CBYI) Receives $7M Capital Funding Proposal To Launch Marijuana Dispensary Card Payment Network
- Colt Resources Inc. (COLTF) CRME transaction and Richard Quesnel appointed Chair Advisory Board
- Consorteum Holdings, Inc. (CSRH) Signs Mobile Application Development Contract With Bet Butler Limited
- eCrypt Technologies, Inc. (ECRY) and Nuwa™ Executive Academy for Security, Defense and Intelligence Professionals enter into a Marketing Alliance
- Global Payout, Inc. (GOHE) European Subsidiary Launches Chip and PIN Prepaid MasterCard® Now Available Internationally
- Great Plains Holdings, Inc. (GTPH) Completes Final Phase of Real Estate Asset Project Ahead of Schedule
- Infinite Group, Inc. (IMCI) Cybersecurity In Focus At IMCI With New Hire
- Innocent, Inc. (INCT) Expands Management Team
- International Stem Cell Corp. (ISCO) Completes Important Study in Parkinson's Disease Program
- Kallo, Inc. (KALO) Announces Appointment of Two Senior Managers
- Mabwe Minerals Inc. (MBMI) Raptor Resources Holdings Issues Update on the Derbyshire Stone Quarry
- NutraNomics, Inc. (NNRX) Whole Food Based Vitamins and Supplements Available on Amazon.com
- P2 Solar, Inc. (PTOS) Signs Implementation Agreement for Rajgarh Hydro Project
- Pan Global Corp. (PGLO) Commences Design Phase for Planned Hydroponic Greenhouse in Northern India
- Raptor Resources Holdings Inc. (RRHI) Issues Update on the Derbyshire Stone Quarry
- Start Scientific, Inc. (STSC) is “One to Watch”
- VistaGen Therapeutics, Inc. (VSTA) Receives Notice of Allowance for Canadian Patent Expanding Stem Cell Technology Platform
- Well Power Inc. (WPWR) Information to be Available through S&P Capital IQ Corporation Records Program
- WordLogic Corp. (WLGC) Announces Development of iOS 8 Version of Award-Winning iKnowU Keyboard
- Zenosense, Inc. (ZENO) Highlights Recent Media Coverage of MRSA